Ví dụ về việc sử dụng Gilead sciences trong Tiếng anh và bản dịch của chúng sang Tiếng việt
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Related companies: Gilead Sciences.
Gilead Sciences, Inc.(NASDAQ: GILD) paid $11.9 billion for Kite Pharma in October, its biggest acquisition ever.
Truvada was developed by Gilead Sciences.
Gilead Sciences and Amgen are among the most profitable drug makers, with net margins of about 35 to 45 percent.
TAF is being developed by Gilead Sciences.
The headquarters of Gilead Sciences in Foster City, California.
The drug is manufactured by Gilead Sciences.
The new pill, made by Gilead Sciences in California, was tested in more than 1,400 patients, in two double-blind clinical trials.
Washington Executive vice president and chief financial officer of Gilead Sciences, Inc.
Biotechnology company Gilead Sciences works in discovering, developing and commercializing therapeutics that help patients improve their health.
Professor Gazzard is being paid adhoc fees for lecturing and/or advice from Gilead Sciences and ViiV.
These studies were conducted by scientists at Gilead Sciences, and successfully optimized ritonavir into a potent CYP3A inhibitor lacking anti-HIV activity.
Radalbuvir(INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus(HCV)infection developed by Gilead Sciences.
It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate(TAF).
By 2020, IMS forecasts 36 million people will have been treated with new medicines for hepatitis C,such as Gilead Sciences' Harvoni, that virtually guarantee a cure for the serious liver disease.
Remdesivir, produced by Gilead Sciences Inc., has been tested on virus patients in China starting in early February, according to U.S. and Chinese officials.
A second study group of 50 people were divided into two groups to test weight-based versus low fixed doses of the experimental drug, sofosbuvir,manufactured by Gilead Sciences in California.
Stribild, which will be marketed by maker Gilead Sciences, contains the HIV drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[1][2]It was developed by Gilead Sciences.
Gilead Sciences made its name developing retroviral drugs to fight HIV, influenza and Hepatitis B and C, and now it's making acquisitions in order to find more bestsellers.
Five leading drug companies- Johnson& Johnson, Regeneron Pharmaceuticals, GlaxoSmithKline,Moderna, and Gilead Sciences- have announced plans to research and develop treatments for the new virus.
It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate(TAF).
Gilead Sciences is an independent biotech company that prides itself on its commitment to corporate responsibility to make its drugs accessible to patients who can't afford them.
As a condition of approval, the drug's manufacturer, Gilead Sciences, Inc., must collect viral isolates from individuals who acquire HIV while taking Truvada™ and evaluate these isolates for the presence of resistance.
Gilead Sciences Inc said it intends to donate as many as 2.4 million bottles of emtricitabine/tenofovir disoproxil fumarate(Truvada) annually to federal efforts to prevent HIV infections.
Gilead Sciences has an active ledipasvir-sofosbuvir patient assistance program for eligible patients with hepatitis C who do not have insurance and do not have coverage through Medicaid or Medicare.
Late last week Gilead Sciences issued a warning about a rare but potentially fatal interaction between its stellar new hepatitis C drug sofosbuvir and amiodarone, a potent but tricky antiarrhythmic agent.
Biotech firm Gilead Sciences donated the most money to charitable causes in 2017- $388 million- according to the Chronicle of Philanthropy's survey of charitable giving by major US companies in 2017.